Mesenchymal Stem Cells for COPD
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to explore how mesenchymal stem cells might benefit individuals with severe chronic obstructive pulmonary disease (COPD), a lung condition that makes breathing difficult. Participants will receive an infusion of these stem cells to determine if their symptoms improve. Ideal candidates are ex-smokers who have experienced a significant COPD flare-up requiring treatment in the past year. This study targets those who can manage daily life with COPD but seek new treatment options. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative therapy.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you are on immunosuppressive medications or have used prednisone or similar corticosteroids within 12 weeks before the study, you may not be eligible to participate.
Is there any evidence suggesting that this treatment is likely to be safe for humans?
Research shows that certain stem cells, called mesenchymal stem cells (MSCs), might help treat long-term lung diseases like COPD (chronic obstructive pulmonary disease). Researchers have tested these stem cells for safety and their potential to improve lung health.
Animal studies have shown positive results, suggesting that MSCs can help with lung problems like emphysema. In human studies, MSCs have generally been safe, with most participants not experiencing serious side effects. Some mild reactions, such as fever or chills, have been reported, but these were uncommon.
Although this trial is in the early stages, MSCs have been studied for other health issues, providing some confidence in their safety. However, since using them for COPD is new, researchers are still learning about all the safety details. Participants should consider this when deciding whether to join the trial.12345Why do researchers think this study treatment might be promising?
Researchers are excited about using mesenchymal stem cells (MSCs) for treating chronic obstructive pulmonary disease (COPD) because this approach is fundamentally different from current treatments. Most existing COPD therapies, like bronchodilators and corticosteroids, focus on easing symptoms and managing inflammation. However, MSCs have the potential to repair and regenerate damaged lung tissue, addressing the root cause of the disease rather than just alleviating symptoms. Additionally, MSCs are administered intravenously, which allows them to travel throughout the body and potentially offer a systemic therapeutic effect, something current localized treatments don't provide. This novel mechanism of action is what makes MSCs a promising option for those with severe COPD.
What evidence suggests that mesenchymal stem cells might be an effective treatment for COPD?
Research has shown that certain stem cells, called mesenchymal stem cells (MSCs), might help treat chronic obstructive pulmonary disease (COPD). Studies have found that MSCs can balance the immune system and heal lung tissue. In lab and animal studies, MSCs have reduced inflammation and repaired damaged lung areas. These cells can regenerate tissue, offering hope for improving lung function in COPD patients. This trial will investigate the effects of MSCs in participants with severe or very severe COPD, who will receive intravenous MSC infusions. Although more research is needed in humans, early results suggest MSCs may provide relief for those with severe COPD.12678
Who Is on the Research Team?
Jorge M Mallea, MD
Principal Investigator
Mayo Clinic
Are You a Good Fit for This Trial?
Adults with advanced COPD who've had a flare-up in the last year, have quit smoking for at least six months, and have specific lung function test results. They must not be pregnant or breastfeeding, have a history of certain diseases like cancer or autoimmune disorders, recent infections requiring antibiotics, or severe heart issues.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive intravenous infusion of Mesenchymal Stem Cells (MSC) for treatment of severe or very severe COPD
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Mesenchymal Stem Cells
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor